Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis C virus NS3/4A protease.

A D Kwong1, J L Kim, G Rao

  • 1Vertex Pharmaceuticals, Inc., Cambridge, MA 02139, USA. kwong@vpharm.com

Antiviral Research
|May 13, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing adaptation and learning in educational environments (SENSE project): a case series study.

Frontiers in psychiatry·2026
Same author

Anomalous vertebral artery course causing radiculopathy: A case report and review of relevant literature.

Brain & spine·2026
Same author

Effectiveness and feasibility of a theory-informed intervention to improve Mediterranean diet adherence, physical activity and cognition in older adults at risk of dementia: the MedEx-UK randomised controlled trial.

BMC medicine·2024
Same author

The impact of transplant location on the gut microbiome and resistome in patients undergoing hematopoietic stem cell transplantation at home versus in the hospital.

bioRxiv : the preprint server for biology·2024
Same author

Long-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative cases.

British journal of haematology·2024
Same author

Value of long non-coding RNA HAS2-AS1 as a diagnostic and prognostic marker of glioma.

Neurologia·2024
Same journal

Nanoparticles in viral pneumonia: diagnosis, therapy, and prevention.

Antiviral research·2026
Same journal

The anti-respiratory syncytial virus activity of biochemicals from Pyrola incarnata.

Antiviral research·2026
Same journal

Ginsenoside Rb2-based inactivation enables a Zika vaccine that maintains pregnancy and protects offspring against virus.

Antiviral research·2026
Same journal

ITGA4 drives pathogenesis of flavivirus and inhibition of it protects mice against Japanese encephalitis virus infection.

Antiviral research·2026
Same journal

Corrigendum to "A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2" [Antivir. Res. 225 (2024) 105854].

Antiviral research·2026
Same journal

Effects of RNA polymerase inhibitors on nucleotidylylation of human norovirus VPg.

Antiviral research·2026
See all related articles

Developing antiviral therapies for hepatitis C virus (HCV) is crucial. This review focuses on inhibitors targeting the HCV NS3/4A serine protease, a key enzyme in viral replication.

Area of Science:

  • Hepatology
  • Virology
  • Drug Discovery

Background:

  • Hepatitis C virus (HCV) infection lacks a broadly effective antiviral therapy.
  • HCV polyprotein processing is essential for viral replication and is catalyzed by the NS3/4A serine protease.
  • The NS3 protein also possesses helicase and NTPase activities vital for viral replication.

Purpose of the Study:

  • To review the structure and function of the HCV NS3/4A serine protease.
  • To discuss the development of small molecule inhibitors targeting this protease activity.

Main Methods:

  • Literature review of studies on HCV NS3/4A protease structure and function.
  • Analysis of research on small molecule inhibitors targeting the NS3/4A protease.

Related Experiment Videos

Main Results:

  • The NS3/4A serine protease forms a complex with NS4A, essential for its activity.
  • Inhibitors targeting the NS3/4A protease are a promising strategy for HCV treatment.

Conclusions:

  • Targeting the NS3/4A serine protease is a key strategy in developing new anti-HCV therapies.
  • Further development of specific small molecule inhibitors holds potential for effective HCV treatment.